Search Bar & Filters
Found 1 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the use of remibrutinib, a Brutons tyrosine kinase BTK inhibitor, in adults with moderate-to-severe papulopustular rosacea PPR. This Phase 2 study aims to determine if remibrutinib can reduce inflammatory lesions on the face while assessing its safety and tolerability in this condition. The study is randomized, double-blind, and placebo-controlled, involving multiple centers. After a screening period of up to 30 days, during which participants must stop certain rosacea treatments and systemic therapies, eligible adults are randomly assigned to receive either remibrutinib or a matching placebo. This treatment phase lasts 16 weeks, followed by a safety follow-up visit about 30 days after the last dose. Participants take the study drug orally. During the trial, participants undergo evaluations of their facial inflammatory lesions at the start and after 16 weeks of treatment. Researchers track changes in lesion counts and severity using an Investigators Global Assessment scale. Safety and tolerability are monitored throughout the study. Total participation includes screening, treatment, and follow-up lasting several months.